絞り込み

16646

広告

「震災の影響確認して判断した」 (デイリースポーツ)

東北電力が再稼働を目指す女川原発2号機(宮城県)が原子力規制委員会の審査に合格したことを受け、規制委の更田豊志委員長は26日の記者会見で「東日本大震災の影響をき...

  1. 東京、京都など4つの国立博物館 あすから...
  2. 米国で新型コロナウイルスに対する世界初の...
  3. 国立がん研究センターなどが日本人肺腺癌の...
  4. 横浜港で検疫中のクルーズ船内で確認された...

ニュース一覧

The obesity epidemic: current and future pharmacological treatments.

著者 Hofbauer KG , Nicholson JR , Boss O
Annu Rev Pharmacol Toxicol.2007 ; 47():565-92.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (36view , 0users)

Full Text Sources

Medical

Miscellaneous

The unabated rise in the prevalence of obesity is a challenge for global health care systems. Efforts to reverse this trend by dietary or behavioral counseling have not been successful, which has stimulated efforts to find a role for pharmacotherapy. Currently only a small number of antiobesity drugs are approved for long-term use and only a few compounds are in clinical development. Despite recent progress in the understanding of the regulation of energy balance, drug discovery has been less productive than expected. In the present review, the clinically available antiobesity agents are discussed. Examples of drug candidates that are currently in development are given and the possible future range of antiobesity agents is illustrated by the targets being addressed in drug discovery. Finally, the efficacy of antiobesity agents and their value in the treatment of obesity are assessed in comparison with other therapeutic approaches, such as surgery and changes in lifestyle.
PMID: 17002599 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード